Axsome Therapeutics (AXSM) Prepaid Assets (2015 - 2026)
Axsome Therapeutics recorded quarterly Prepaid Assets of $23.5 million in Q1 2026, up 72.32% quarter-over-quarter from $13.7 million in Q4 2025, and up 46.95% year-over-year from $16.0 million in Q1 2025.
Axsome Therapeutics' Prepaid Assets history runs 12 years deep, the most recent figure standing at $23.5 million for Q1 2026.
- In Q1 2026, Prepaid Assets rose 46.95% year-over-year to $23.5 million; the TTM figure through Mar 2026 stood at $23.5 million (up 46.95% YoY), while the FY2025 annual figure was $13.7 million, up 13.97% from the prior year.
- Prepaid Assets came in at $23.5 million for Q1 2026 at Axsome Therapeutics, up from $13.7 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $23.5 million in Q1 2026 to a low of $2.1 million in Q1 2022.
- A 5-year average of $10.4 million and a median of $11.8 million in 2024 frame the typical range for Prepaid Assets.
- Across the five-year window, Prepaid Assets jumped 6040.97% in 2022 and gained 13.97% in 2025, its largest moves.
- Axsome Therapeutics' Prepaid Assets stood at $2.8 million in 2022, then soared by 191.8% to $8.1 million in 2023, then jumped by 47.6% to $12.0 million in 2024, then grew by 13.97% to $13.7 million in 2025, then surged by 72.32% to $23.5 million in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $23.5 million, $13.7 million, and $19.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Axsome Therapeutics | 11.82 Bn | 11.51 Bn | 176.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.52 Mn |
| Dec 31, 2025 | 13.65 Mn |
| Sep 30, 2025 | 19.79 Mn |
| Jun 30, 2025 | 16.34 Mn |
| Mar 31, 2025 | 16.01 Mn |
| Dec 31, 2024 | 11.98 Mn |
| Sep 30, 2024 | 13.41 Mn |
| Jun 30, 2024 | 11.81 Mn |
| Mar 31, 2024 | 12.03 Mn |
| Dec 31, 2023 | 8.12 Mn |
| Sep 30, 2023 | 6.80 Mn |
| Jun 30, 2023 | 5.91 Mn |
| Mar 31, 2023 | 5.20 Mn |
| Dec 31, 2022 | 2.78 Mn |
| Sep 30, 2022 | 2.46 Mn |
| Jun 30, 2022 | 4.09 Mn |
| Mar 31, 2022 | 2.12 Mn |
| Dec 31, 2021 | 45,286.00 |
| Sep 30, 2021 | 401,302.00 |
| Jun 30, 2021 | 435,804.00 |
| Mar 31, 2021 | 375,306.00 |
| Dec 31, 2020 | 148,373.00 |
| Sep 30, 2020 | 911,992.00 |
| Jun 30, 2020 | 137,181.00 |
| Mar 31, 2020 | 309,370.00 |
| Dec 31, 2019 | 413,095.00 |
| Sep 30, 2019 | 594,345.00 |
| Jun 30, 2019 | 814,913.00 |
| Mar 31, 2019 | 1.13 Mn |
| Dec 31, 2018 | 1.25 Mn |
| Sep 30, 2018 | 723,669.00 |
| Jun 30, 2018 | 1.19 Mn |
| Mar 31, 2018 | 1.12 Mn |
| Dec 31, 2017 | 1.28 Mn |
| Sep 30, 2017 | 746,094.00 |
| Jun 30, 2017 | 842,597.00 |
| Mar 31, 2017 | 1.18 Mn |
| Dec 31, 2016 | 1.38 Mn |
| Sep 30, 2016 | 867,099.00 |
| Jun 30, 2016 | 1.16 Mn |
| Mar 31, 2016 | 987,552.00 |
| Dec 31, 2015 | 996,618.00 |